Article

Vitrectomy possible treatment for diabetic macular edema

Vitrectomy should be considered for some eyes with diabetic macular edema (DME), according to Tarek Hassan, MD, who spoke during the retina subspecialty day at the American Academy of Ophthalmology annual meeting.

Chicago-Vitrectomy should be considered for some eyes with diabetic macular edema (DME), according to Tarek Hassan, MD, who spoke during the retina subspecialty day at the American Academy of Ophthalmology annual meeting.

Dr. Hassan, who is assistant professor of Biomedical Sciences, Oakland University, Royal Oak, MI, explained that eyes with diffuse clinically significant DME-which do not respond as well to laser treatment as focal clinically significant DME-may benefit from vitrectomy because of studies over more than a decade that have indicated that vitrectomy membrane peeling with or without internal limiting membrane peeling relieves posterior hyaloid traction and can result in visual improvement in these eyes thought to be refractory to treatment.

Numerous studies have shown visual improvement in eyes with a visibly taut, opacified posterior hyaloid membrane; with an attached but not clinically visible taut posterior hyaloid membrane; with a preoperative detached posterior hyaloid; and with massive subfoveal hard exudates.

There are questions about how vitrectomy works in these eyes, but evidence seems to indicate that vitrectomy relieves the anteroposterior vitreomacular traction and the tangential traction. The role of the internal limiting membrane seems important and its removal ensures the elimination of all posterior hyaloidal traction and decreases the recurrence of clinical significant DME after vitrectomy. Better visual prognosis may be expected in eyes with a short duration of clinically significant DME, little or no macular ischemia, mild preoperative laser treatment, an obvious taut posterior hyaloid, good preoperative visual acuity, and no preoperative foveal hard exudates, he explained.

“Vitrectomy should be thought of as a long-term efficacious treatment for some eyes with refractory macular edema. The role of vitrectomy must be defined and compared with intravitreal triamcinolone and laser treatment, but vitrectomy may provide a more permanent solution for some eyes,” Dr. Hassan said. “The vitreomacular interface is the key and optical coherence tomography must help demonstrate posterior hyaloid traction whether it is anteroposterior or tangential in its dimension.

“Ultimately, vitrectomy should be in all surgeons’ armamentarium for this disease because it does stabilize or improve vision in eyes that would otherwise worsen,” Dr. Hassan said. He looked to the future for possible combination therapies with vasopermeability inhibitors.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.